Icotinib Hydrochloride in Treating Patients With Advanced Cancers
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of icotinib hydrochloride in
treating patients with advanced cancers. Icotinib hydrochloride may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth.